Key takeaways:
- Postmenopausal women on hormone therapy had higher total body weight loss with semaglutide for up to 12 months vs. no hormone therapy.
- Cardiometabolic risk markers improved with and without hormone therapy use.
Hormone therapy was associated with an improved weight-loss response for postmenopausal women with overweight or obesity treated with semaglutide, according to cohort study results published in Menopause.
Currently, semaglutide (Novo Nordisk) is approved for the treatment of overweight and obesity leading to a mean weight loss of 15% after 68 weeks, the researchers wrote.
